In India, the COVID-19 vaccination drive has begun. To be clear, the two vaccines – Covaxin and Covishield – are different from each other.
The third phase began on April 1, in which people over the age of 18 can take life-saving shots. However, as of now, people do not have a say regarding which vaccine they want to get. Hopefully, this decision will change soon.
The Coronavirus is a serious illness and it’s important to be vigilant and informed. It’s easy to become overwhelmed with the onslaught of information, but don’t worry. We’ve compiled everything for you here.
Developer of covaxin
With so many resources going into examining COVID-19, every day brings a new discovery about its effects on us. The latest complication from this virus is diabetes. Though the two conditions are not related, it’s clear that diabetes after COVID-19 is something that medical professionals will be paying a lot of attention to.
Delta COVID is proving to be more infectious than the other variants. Covaxin makers are conducting a study to determine the effectiveness of the third dose of Covaxin. The expected results will be release in November 2021.
Covishield is a product that the Oxford-AstraZeneca and Serum Institute of India (SII) have teamed up to manufacture and distribute. There are some doctors who are questioning whether it’s necessary for Covishield to have booster doses or not. Covishield was develope in association with Oxford-AstraZeneca, and some doctors think that the elderly population and people with comorbidities might not be able to produce the desired immune response to the Delta variant.
Type of Vaccine
Covaxin is a vaccine made with Whole-Virion Inactivate Vero Cell-derived technology. It contains inactive viruses which are safe but still teach the immune system to prepare for the real thing. These days, there are a variety of vaccine options. These new vaccines have the same technology as the old ones—to protect us from a diverse range of diseases. Here are a few examples:
- Seasonal influenza
- Pertussis, and
- Japanese encephalitis
Covishield has been prepare using the viral vector platform which is a totally different technology.
A chimpanzee adenovirus – ChAdOx1 – has been modify to enable it to carry the COVID-19 spike protein into the cells of humans. This cold virus is incapable of infecting people but can teach the immune system to be ready for such viruses by introducing the same protein. A chimpanzee adenovirus – ChAdOx1 – has been modified so it can carry the COVID-19 spike protein into the cells of humans.
In terms of dosage, the two vaccines are the same. They both measure out to 0.5ml and are administer in the arm region. Both of these vaccines use a specific type of technology that was use to prepare vaccines for viruses like Ebola. Although the vaccination schedules vary, the dosing cycles for Covaxin and Covishield are different. Covaxin’s second dose is given four to six weeks after the first, while Covishield’s second dose is given 84 days or 12 to sixteen weeks after the first.
The best temperature for Covishield and Covaxin is 2-8° Centigrade, which is what most refrigerators are set to in India.
The vaccines here are ship and stored at the same temperature, so both the Covishield and Covaxin will be at their best.
Covishield and Covaxin have both shown promising results in India. The effectiveness of Covishield is nearly 90% globally, and Covaxin’s is 81% according to interim 3rd phase trial results. This also makes the transport and storage of these vaccines easier.
After receiving a vaccination, it is normal to feel pain at the site of injection; some people may also experience side effects such as headaches, joint pain, fever, and feeling feverish. These symptoms generally go away after a day or two.
The latest updates on the COVID vaccine
- COVID vaccine has reached 126 million doses administered in India, with more than 462 million people fully vaccinated. The COVID vaccine is effective against the mutated UK/South Africa/Brazil virus.
- The COVID vaccine has been administer to 462 million people in India, with 126 million doses. More than half have receive two doses of the vaccine and are consider fully vaccinate. Covaxin and Covishield are both effective against the mutated UK/South Africa/Brazil virus.
- The Russian vaccine Sputnik V has been given emergency use authorization in India. The vaccine will be produce by Dr. Reddy’s Laboratories in India. A recent study found no strong allergies to the drug.
- India will produce 850 million doses of Sputnik V every year.
- The Russian vaccine is more effective than Covishield (90% effectiveness) or Covaxin (81% effectiveness) for the prevention of the flu.
- Bharat Biotech has announce that the production of Covaxin will be increase to 12 million doses per month. The vaccine will be deliver to India this month and will be used in the fight against coronavirus. This is not the first vaccine against coronavirus in India, but it will be available for sale at a lower price than the other two, meaning its usage may surpass 50 million doses per month.
- Now that vaccines will be available in the open market, manufacturers will also be able to decide the price of each dose. A study has found that COVID is extremely unlikely to show up in tests after the second dose for Covaxin or Covishield. Lactating and pregnant women can also take the vaccine.